title: [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease.
abstract: BACKGROUND
  In vivo imaging of the dopamine transporter with [99mTc]TRODAT-1 (TRODAT) and olfactory testing have both been proposed as potential biomarkers in Parkinson disease (PD).
  
  
  OBJECTIVE
  To evaluate the relationship between TRODAT SPECT imaging, odor identification skills, and motor function in patients with early PD.
  
  
  METHODS
  Twenty-four patients with a clinical diagnosis of early-stage PD (mean Hoehn & Yahr stage = 1.4) underwent TRODAT imaging, Unified PD Rating Scale (UPDRS) ratings of motor function, and administration of the University of Pennsylvania Smell Identification Test (UPSIT). Brain images were obtained using a standardized processing protocol and specific uptake ratios for striatal regions of interest were calculated. Partial correlations between the imaging indices, disease duration, UPSIT scores, and UPDRS motor scores were then calculated.
  
  
  RESULTS
  UPSIT scores were correlated with TRODAT uptake in the striatum as a whole (r = 0.66, p = 0.001). The putamen showed the strongest correlation with the UPSIT (r = 0.74; p < 0.001). The correlation between dopamine transporter density in the caudate and UPSIT was moderate (r = 0.36, p = 0.11), but was not significant.
  
  
  CONCLUSIONS
  Olfactory function is highly correlated with dopamine transporter imaging abnormalities in early Parkinson disease (PD). Further studies are warranted to determine whether changes over time in these two measures are also correlated in early PD.
authors.affiliation: Parkinson Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania, Philadelphia, USA. siderowa@pahosp.com
authors.forename: A
authors.initials: A
authors.lastname: Siderowf
authors.forename: A
authors.initials: A
authors.lastname: Newberg
authors.forename: K L
authors.initials: KL
authors.lastname: Chou
authors.forename: M
authors.initials: M
authors.lastname: Lloyd
authors.forename: A
authors.initials: A
authors.lastname: Colcher
authors.forename: H I
authors.initials: HI
authors.lastname: Hurtig
authors.forename: M B
authors.initials: MB
authors.lastname: Stern
authors.forename: R L
authors.initials: RL
authors.lastname: Doty
authors.forename: P D
authors.initials: PD
authors.lastname: Mozley
authors.forename: N
authors.initials: N
authors.lastname: Wintering
authors.forename: J E
authors.initials: JE
authors.lastname: Duda
authors.forename: D
authors.initials: D
authors.lastname: Weintraub
authors.forename: P J
authors.initials: PJ
authors.lastname: Moberg
mesh_terms: D000377:Agnosia / Q000000981:diagnostic imaging* / Q000209:etiology / Q000503:physiopathology; D001667:Binding, Competitive / Q000502:physiology; D003342:Corpus Striatum / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology; D018450:Disease Progression; D004298:Dopamine / Q000172:deficiency; D050483:Dopamine Plasma Membrane Transport Proteins / Q000032:analysis* / Q000378:metabolism; D009460:Neurologic Examination; D009833:Olfactory Pathways / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology; D015609:Organotechnetium Compounds / Q000378:metabolism / Q000493:pharmacokinetics; D010300:Parkinson Disease / Q000150:complications / Q000000981:diagnostic imaging* / Q000503:physiopathology; D011237:Predictive Value of Tests; D011379:Prognosis; D019275:Radiopharmaceuticals; D012903:Smell / Q000502:physiology; D009435:Synaptic Transmission / Q000502:physiology; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*; D014326:Tropanes / Q000378:metabolism / Q000493:pharmacokinetics
chemical_list: D050483:Dopamine Plasma Membrane Transport Proteins; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D014326:Tropanes; C104196:technetium Tc 99m TRODAT-1; D004298:Dopamine